Impact of Sex on 3-Year Outcome After Percutaneous Coronary Intervention Using Bare-Metal and Drug-Eluting Stents in Previously Untreated Coronary Artery DiseaseInsights From the RESEARCH (Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated at Rotterdam Cardiology Hospital) Registries
Yoshinobu Onuma, MD,
Neville Kukreja, MA,
Joost Daemen, MD,
Hector M. Garcia-Garcia, MD, MSc,
Nieves Gonzalo, MD,
Jin Ming Cheng, MSc,
Piet Hein van Twisk, MSc,
Ron van Domburg, MD, PhD,
Patrick W. Serruys, MD, PhD* on behalf of the Interventional Cardiologists of Thoraxcenter
Thoraxcenter, Erasmus Medical Center, Rotterdam, the Netherlands
View larger version (19K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 1 A Flowchart of Patient Selection
Out of 5,358 patients who underwent percutaneous intervention in a single center from 2000 to 2004, 4,936 patients were included in this analysis after exclusion of 422 patients. BMS = bare-metal stent(s); DES = drug-eluting stent(s).
|
|
View larger version (17K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 2 Kaplan-Meier Curve of MACE up to 3 Years After Index Procedure Among 4 Groups
Major adverse cardiac event (MACE) rates were significantly lower in women (solid red line) and men (dotted red line) treated with DES than in patients of both sexes treated with BMS (solid black line for women, dotted black line for men). Abbreviations as in Figure 1.
|
|
View larger version (22K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 3 Adjusted Hazard Ratio of Women Versus Men on MACE at Year 3 in Subgroups
Female sex was not associated with differential MACE risk from male sex in any groups except for those presenting with acute myocardial infarction (adjusted HR women vs. men: 1.37 [95% CI: 1.02 to 1.85]). CI = confidence interval; HR = hazard ratio; other abbreviations as in Figure 2.
|
|
|
